PCSK9 inhibitors
Novel Gene Therapy Slashes LDL in Patients With Hypercholesterolemia
VERVE-101, a novel gene therapy using liquid nanoparticles to edit the PCSK9 gene, reduced LDL cholesterol ...
NOVEMBER 17, 2023
Early Treatment With Repatha Lowered Incidence of CV Death, Other Events
Long-term treatment with evolocumab in adults with atherosclerosis lowered the incidence of major cardiovascular ...
SEPTEMBER 8, 2022
Amgen Lowers List Price for Repatha for Everyone
Effective Dec. 31, 2019, evolocumab will be distributed exclusively at the 60% lower list price of $5,850 per year ...
OCTOBER 24, 2019
Cost of Praluent PCSK9 Inhibitor Lowered for Medicare Patients
The cost of Praluent, regardless of dose, will be $5,850 annually, a 60% reduction from the original price.
FEBRUARY 12, 2019
Some Still Apprehensive About PCSK9 Therapy
Even when prescriptions for costly PCSK9 inhibitors are approved by insurers for the management of low-density ...
AUGUST 30, 2018
PBM Abarca Announces Outcomes-Based Contract for Amgen’s Evolocumab
Innovative PBM Abarca has entered into an outcomes-based contract for the PCSK9 inhibitor evolocumab with Amgen, ...
MARCH 9, 2018
New Indication Granted for Repatha for Wider Group of Patients: Adults with CVD
Repatha's indication had been limited to patients with homozygous familial hypercholesterolemia who require ...
DECEMBER 2, 2017
Most Insurers Denying Claims for PCSK9 Inhibitors
PCSK9 inhibitors, such as Repatha and Praluent have been shown to reduce low-density lipoprotein by 60% and ...
NOVEMBER 29, 2017
PCSK9s Effective, but Give Statins a Chance
Although the exact role of LDL cholesterol–lowering drugs in managing cardiovascular disease is still being ...
JUNE 4, 2017
Elevated Cataract Risk Seen in Some PCSK9-Treated Patients
PCSK9 inhibitors can reduce a high percentage of LDL cholesterol in high-risk patients, but there have been some ...
FEBRUARY 1, 2017
